標(biāo)題: Titlebook: Bortezomib in the Treatment of Multiple Myeloma; Irene M. Ghobrial,Paul G. Richardson,Kenneth C. An Book 2011 Springer Basel AG 2011 Borte [打印本頁(yè)] 作者: Racket 時(shí)間: 2025-3-21 16:13
書目名稱Bortezomib in the Treatment of Multiple Myeloma影響因子(影響力)
書目名稱Bortezomib in the Treatment of Multiple Myeloma影響因子(影響力)學(xué)科排名
書目名稱Bortezomib in the Treatment of Multiple Myeloma網(wǎng)絡(luò)公開度
書目名稱Bortezomib in the Treatment of Multiple Myeloma網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Bortezomib in the Treatment of Multiple Myeloma被引頻次
書目名稱Bortezomib in the Treatment of Multiple Myeloma被引頻次學(xué)科排名
書目名稱Bortezomib in the Treatment of Multiple Myeloma年度引用
書目名稱Bortezomib in the Treatment of Multiple Myeloma年度引用學(xué)科排名
書目名稱Bortezomib in the Treatment of Multiple Myeloma讀者反饋
書目名稱Bortezomib in the Treatment of Multiple Myeloma讀者反饋學(xué)科排名
作者: Anguish 時(shí)間: 2025-3-21 20:20
Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics,lls and osteoblasts in the bone marrow milieu. Importantly, combination treatment strategies, including histone deacetylase inhibitors, Akt inhibitor, lenalidomide, heat shock protein 90 inhibitors, and aurora kinase inhibitors demonstrate significant anti-MM activities both in preclinical and clini作者: Gudgeon 時(shí)間: 2025-3-22 01:53
Bortezomib in the Upfront Treatment of Multiple Myeloma,sed combinations. In patients who are not candidates for transplant, bortezomib in combination with melphalan and prednisone has also proved to be superior to conventional therapy, with high overall and CR rates and a significantly longer time to progression and overall survival. Moreover, new strat作者: Pde5-Inhibitors 時(shí)間: 2025-3-22 08:13
The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma,ation of remission. Finally, modifying the conditioning regimen itself represents yet another method by which the efficacy of autologous transplant can be further enhanced. These strategies to improve the outcomes of the transplant process for patients with multiple myeloma are currently the focus o作者: CURL 時(shí)間: 2025-3-22 10:53
Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma,se findings have rightfully entrenched bortezomib as one of the most important parts of our chemotherapeutic armamentarium against multiple myeloma. In this chapter, we will review the role of bortezomib as a single-agent, and in combination with other chemotherapeutics, to combat myeloma in the rel作者: MURAL 時(shí)間: 2025-3-22 16:50 作者: leniency 時(shí)間: 2025-3-22 17:05
,?konomische Gestaltungsimplikationen,tors suggested other therapeutic possibilities; for example, its role in the activation of the NF-κB suggested anti-inflammatory and antineoplastic actions and led to clinical trials against various cancers. Indications of the special sensitivity of multiple myeloma were observed in Phase I trials, 作者: 煩人 時(shí)間: 2025-3-23 00:44
Logistik im Zwischenwerksverkehrlls and osteoblasts in the bone marrow milieu. Importantly, combination treatment strategies, including histone deacetylase inhibitors, Akt inhibitor, lenalidomide, heat shock protein 90 inhibitors, and aurora kinase inhibitors demonstrate significant anti-MM activities both in preclinical and clini作者: 消滅 時(shí)間: 2025-3-23 04:49
Systemlogistik und Logistiksysteme,sed combinations. In patients who are not candidates for transplant, bortezomib in combination with melphalan and prednisone has also proved to be superior to conventional therapy, with high overall and CR rates and a significantly longer time to progression and overall survival. Moreover, new strat作者: 寒冷 時(shí)間: 2025-3-23 07:07 作者: 纖細(xì) 時(shí)間: 2025-3-23 09:51
Logistik in Dienstleistungsunternehmense findings have rightfully entrenched bortezomib as one of the most important parts of our chemotherapeutic armamentarium against multiple myeloma. In this chapter, we will review the role of bortezomib as a single-agent, and in combination with other chemotherapeutics, to combat myeloma in the rel作者: 游行 時(shí)間: 2025-3-23 17:41
Niels Bugert,Maximilian Sch?pfelr a number of ongoing studies looking at combination with conventional regimens used in MCL either with chemoimmunotherapy or as consolidation or maintenance approaches post-induction. The progress in understanding MCL biology especially regarding the heterogeneity of the disease as well as emerging作者: 姑姑在炫耀 時(shí)間: 2025-3-23 21:11
2296-6056 h on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.978-3-7643-8948-2Series ISSN 2296-6056 Series E-ISSN 2296-6064 作者: 北極人 時(shí)間: 2025-3-24 00:49 作者: Ophthalmologist 時(shí)間: 2025-3-24 04:03
Milestones in Drug Therapyhttp://image.papertrans.cn/b/image/189905.jpg作者: 同位素 時(shí)間: 2025-3-24 09:26
,?konomische Gestaltungsimplikationen, protein breakdown. The primary route for degradation of intracellular proteins is the ubiquitin–proteasome pathway, in which protein substrates are linked to ubiquitin chains, which marks them for degradation by the large proteolytic complex, the 26S proteasome. It utilizes ATP to unfold protein su作者: Lobotomy 時(shí)間: 2025-3-24 13:17 作者: 無(wú)思維能力 時(shí)間: 2025-3-24 16:50
Logistik im Zwischenwerksverkehrtients and is now being used as a platform for combinations with other new agents for myeloma. In addition to its anti-myeloma effect, bortezomib also targets the bone microenvironment and can inhibit osteoclast formation and stimulate osteoblast activity in patients with myeloma. Potentially, combi作者: anthesis 時(shí)間: 2025-3-24 19:51 作者: candle 時(shí)間: 2025-3-25 03:05 作者: omnibus 時(shí)間: 2025-3-25 03:32 作者: 褻瀆 時(shí)間: 2025-3-25 09:06 作者: xanthelasma 時(shí)間: 2025-3-25 12:12
Niels Bugert,Maximilian Sch?pfel research due to its typical poor outcome. Besides a small subset of patients who can enjoy long-term disease-frees urvival through non-myeloablative allogenic stem cell transplant, most patients relapse and become frequently over time chemoresistant to conventional or high-dose cytotoxic-based ther作者: orthopedist 時(shí)間: 2025-3-25 18:13 作者: Favorable 時(shí)間: 2025-3-25 20:14
Logistik in Wissenschaft und Praxis only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced resp作者: FIG 時(shí)間: 2025-3-26 03:33 作者: bizarre 時(shí)間: 2025-3-26 07:43
https://doi.org/10.1007/978-3-7643-8948-2Bortezomib; Cancer therapy; Multiple Myeloma; Oncology; Pharmacology; Proteasome inhibitors; Velcade; Apopt作者: upstart 時(shí)間: 2025-3-26 09:15
Springer Basel AG 2011作者: 懶惰民族 時(shí)間: 2025-3-26 16:21 作者: 同步左右 時(shí)間: 2025-3-26 17:23 作者: 無(wú)關(guān)緊要 時(shí)間: 2025-3-26 23:46 作者: 退潮 時(shí)間: 2025-3-27 04:22 作者: 即席演說(shuō) 時(shí)間: 2025-3-27 05:31
https://doi.org/10.1007/978-3-658-33480-2nosporamide A (NPI-0052). These agents differ from bortezomib in some of their key characteristics, and differences in their pharmacology may result in different activity and safety profiles. This chapter reviews the second-generation proteasome inhibitors, together with other potential therapeutic targets in the ubiquitin–proteasome system.作者: 制度 時(shí)間: 2025-3-27 13:06 作者: arrogant 時(shí)間: 2025-3-27 16:49 作者: 尋找 時(shí)間: 2025-3-27 20:35
Second-Generation Proteasome Inhibitors,nosporamide A (NPI-0052). These agents differ from bortezomib in some of their key characteristics, and differences in their pharmacology may result in different activity and safety profiles. This chapter reviews the second-generation proteasome inhibitors, together with other potential therapeutic targets in the ubiquitin–proteasome system.作者: 氣候 時(shí)間: 2025-3-28 01:52
2296-6056 s and clinicians from the fields of oncology and pharmacologMultiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsibl作者: 兩種語(yǔ)言 時(shí)間: 2025-3-28 04:29
Book 2011 in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.作者: Reverie 時(shí)間: 2025-3-28 07:02
Julia Braun,Magdalena Mi?ler-Behrs. The enthusiastic preclinical and clinical results exerted by bortezomib in multiple myeloma, as well as other hematological malignancies including WM, has validated the idea that the proteasome is an important target in cancer therapy.作者: 傲慢物 時(shí)間: 2025-3-28 13:57 作者: ARIA 時(shí)間: 2025-3-28 14:56
,Bortezomib in Waldenstrom’s Macroglobulinemia,s. The enthusiastic preclinical and clinical results exerted by bortezomib in multiple myeloma, as well as other hematological malignancies including WM, has validated the idea that the proteasome is an important target in cancer therapy.作者: 蕁麻 時(shí)間: 2025-3-28 21:17 作者: 調(diào)味品 時(shí)間: 2025-3-29 01:21 作者: 虛弱的神經(jīng) 時(shí)間: 2025-3-29 03:36
Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics,ar protein complexes that degrade polyubiquitinated proteins. Bortezomib (Velcade.) is a boronic acid dipeptide that directly binds to enzymatic complex to block chimotrypsin-like activity of proteasome and is the first FDA-approved proteasome inhibitor for multiple myeloma (MM) treatment. Bortezomi作者: negligence 時(shí)間: 2025-3-29 09:13 作者: A保存的 時(shí)間: 2025-3-29 15:21 作者: 奇思怪想 時(shí)間: 2025-3-29 16:57
